Alex Yule, PhD

Recent Posts

The Rise and Rise of Antibody-Drug Conjugates

The path of the "magic bullet" Around the turn of the last century, Paul Ehrlich postulated that tailored and targeted drug delivery might be a means of treating disease1. Some eighty years later,...
Learn More

The race is on: after almost six decades, RSV vaccines near the finish line

The COVID-19 pandemic established that, when push comes to shove, successful vaccine development and deployment can be conducted at breakneck speed, even when largely untried and untested...
Learn More

Targeted Radiotherapy: The Comeback Kid of Cancer Treatment?

The notion that a systemically administered source of radiation can be usefully directed towards a tumor has been exploited since the 1940s, when radioiodine was introduced as a treatment for thyroid...
Learn More

Moving beyond cancer: CAR-T therapy takes on autoimmune disease

It’s not untypical for an emerging cancer treatments to be dubbed “revolutionary” or “game-changing”, but stepping beyond cliché, chimeric antigen receptor T-cell (“CAR-T”) therapy can rightly be...
Learn More

Monetizing the microbiome

Based on some neat guesstimating1, the number of bacteria in the gut roughly equals the number of cells in our bodies, so it’s no surprise that such a substantial (around 200g in a 70kg adult) and...
Learn More
1

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.